SecSonar.com

Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Arcus Biosciences, Inc. (RCUS) is a Biotechnology company based in US with a market capitalization of $2.5B. Revenue declined 4.3% year-over-year and free cash flow was negative at -$484M. This page tracks RCUS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 627 employees · IPO Mar 15, 2018

Valuation

Valuation & price

$23.78 · as of May 17, 2026 · -23.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.02

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$31.00$19.61$8.22Jul 25Dec 25Jul 26Jul 7, 25$8.22Jul 9, 25$9.33Jul 11, 25$9.33Jul 15, 25$9.03Jul 17, 25$9.42Jul 21, 25$9.26Jul 23, 25$9.75Jul 25, 25$10.23Jul 29, 25$9.61Jul 31, 25$9.13Aug 4, 25$9.23Aug 6, 25$9.49Aug 11, 25$9.16Aug 13, 25$10.06Aug 15, 25$10.39Aug 19, 25$10.06Aug 21, 25$10.48Aug 25, 25$10.15Aug 27, 25$10.56Aug 29, 25$10.59Sep 3, 25$11.64Sep 5, 25$12.19Sep 9, 25$11.32Sep 11, 25$11.50Sep 16, 25$11.75Sep 18, 25$12.44Sep 22, 25$12.52Sep 24, 25$12.51Sep 26, 25$12.84Sep 30, 25$13.60Oct 2, 25$13.37Oct 6, 25$14.48Oct 8, 25$15.05Oct 10, 25$14.60Oct 14, 25$15.62Oct 16, 25$16.60Oct 21, 25$18.05Oct 23, 25$16.78Oct 27, 25$18.60Oct 29, 25$20.29Oct 31, 25$19.72Nov 4, 25$19.83Nov 6, 25$19.56Nov 10, 25$19.46Nov 12, 25$20.00Nov 14, 25$20.07Nov 18, 25$20.19Nov 20, 25$21.23Nov 25, 25$24.28Nov 28, 25$26.10Dec 2, 25$25.43Dec 4, 25$25.26Dec 8, 25$25.80Dec 10, 25$25.40Dec 12, 25$21.53Dec 16, 25$22.20Dec 18, 25$21.99Dec 22, 25$23.22Dec 24, 25$23.12Dec 29, 25$23.33Jan 2, 26$23.29Jan 6, 26$21.69Jan 8, 26$21.35Jan 12, 26$21.30Jan 14, 26$24.56Jan 16, 26$21.80Jan 21, 26$22.95Jan 23, 26$22.13Jan 27, 26$22.99Jan 29, 26$21.79Feb 2, 26$21.66Feb 4, 26$20.99Feb 9, 26$21.13Feb 11, 26$21.36Feb 13, 26$18.92Feb 18, 26$19.43Feb 20, 26$18.99Feb 24, 26$20.19Feb 26, 26$19.54Mar 2, 26$23.94Mar 4, 26$22.68Mar 6, 26$22.11Mar 10, 26$24.56Mar 12, 26$22.70Mar 17, 26$22.59Mar 19, 26$22.43Mar 23, 26$21.41Mar 25, 26$21.46Mar 27, 26$20.28Mar 31, 26$21.60Apr 2, 26$22.96Apr 7, 26$22.07Apr 9, 26$23.28Apr 13, 26$22.39Apr 15, 26$23.70Apr 17, 26$24.25Apr 22, 26$26.62Apr 24, 26$25.50Apr 28, 26$24.80Apr 30, 26$25.50May 4, 26$26.05May 6, 26$26.00May 8, 26$25.36May 12, 26$24.90May 14, 26$24.95May 18, 26$23.40May 20, 26$23.74May 22, 26$23.43May 28, 26$24.48Jun 1, 26$25.67Jun 3, 26$23.86Jun 5, 26$23.19Jun 9, 26$23.64Jun 11, 26$23.30Jun 15, 26$24.18Jun 17, 26$24.12Jun 22, 26$27.23Jun 24, 26$28.80Jun 26, 26$31.00Jul 2, 26$30.33
$8.2252-week range$31.08
Loading valuation history…

Fundamentals

Key fundamentals

$2.5B

Market cap

-4.3%

Revenue growth (YoY)

96.0%

Gross margin

-$484M

Free cash flow (USD)

-$882M

Net debt

Net cash position

19.2%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$1.4MFY 2018$8.4MFY 2019$15.0MFY 2020$78.0MFY 2021$383.0MFY 2022$112.0MFY 2023$117.0MFY 2024$258.0MFY 2025$247.0M
$0$247M

Free cash flow by year

2016 → 2025

FY 2016$-17.0MFY 2017$-30.6MFY 2018$-46.7MFY 2019$-75.4MFY 2020$108.1MFY 2021$-282.2MFY 2022$432.0MFY 2023$-330.0MFY 2024$-176.0MFY 2025$-484.0M
-$17M-$484M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202596.0%
100.0%96.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $878K · 10b5-1 PlanJaen Juan C. · President · $877.5KJun 24, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 12, 2026Filing
  • Insider sellInsider Sell $66K · 10b5-1 PlanAzoy Alexander · Chief Accounting Officer · $66KJun 1, 2026Filing
  • Insider sellInsider Sell $199K · 10b5-1 PlanGoeltz II Robert C. · Chief Financial Officer · $199KMay 12, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • 8-K eventStudy DiscontinuationApr 20, 2026Filing

Questions

Frequently asked questions

What is Arcus Biosciences, Inc.'s market cap?

Arcus Biosciences, Inc. (RCUS) has a market capitalization of $2.5B.

What is RCUS's P/E ratio?

A meaningful P/E ratio is not available for RCUS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is RCUS's price-to-book (P/B) ratio?

RCUS trades at 4.02 times book value per share.

Are insiders buying RCUS stock?

SEC Form 4 filings show no open-market insider buys at Arcus Biosciences, Inc. in the last 90 days (3 sells).

Same arena

Related companies in Biotechnology

TARS

Tarsus Pharmaceuticals, Inc.

$2.6B

IDYA

IDEAYA Biosciences, Inc.

$2.6B

ADPT

Adaptive Biotechnologies Corporation

$2.5B

TNGX

Tango Therapeutics, Inc.

$2.4B

ALMS

Alumis Inc. Common Stock

$2.7B

ARQT

Arcutis Biotherapeutics, Inc.

$2.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.